FF-10501: Phase I/IIa started

Fujifilm's Fujifilm Corp. subsidiary began an open-label, dose-escalation, U.S. Phase I/IIa trial of oral FF-10501 given twice daily for the first 14 days of a 28-day cycle in about 56 patients with r...